LONDON, UK, March 14, 2024 – Prokarium announces they have been awarded a UK Research and Innovation (UKRI) Engineering Biology grant funded through the UKRI Technology Missions Fund, delivered by Innovate UK. These funds will serve as a catalyst for Prokarium’s cutting-edge Living Cures platform, poised to revolutionize precision medicine by introducing off-the-shelf programmable therapeutics, thereby ushering in a novel era of immunotherapies with equitable access.
Prokarium’s CEO, Kristen Albright, PharmD remarked, “Receiving this UKRI Engineering Biology grant is a testament to Prokarium’s commitment to advancing the use of synthetic biology in the field of oncology. We are grateful for the recognition and support from UKRI, and this grant will undoubtedly accelerate our efforts to bring transformative therapies to patients globally.”
The CSO, Livija Deban, PhD of Prokarium added, “The use of synthetic biology in our Living Cures platform represents a leap forward in therapeutic innovation. With this grant, we are poised to unlock new dimensions in precision medicine, making programmable therapeutics more accessible and scalable than ever before.”
Prokarium looks forward to the next phase of development, leveraging the UKRI Engineering Biology grant to drive progress and further solidify its position as a leader in the synthetic biology landscape.
About Prokarium
Prokarium is a clinical-stage biopharmaceutical company bioengineering Living Cures by combining cutting edge synthetic biology tools with AI-enabled discovery. Prokarium’s lead program, currently advancing in US clinical trials for bladder cancer, is a single-dose therapy redesigning the treatment paradigm for patients. The Company’s Living Cures platform aims to transform precision medicine into off-the-shelf programmable therapeutics, promising a new class of immunotherapies with a goal of equitable access.
For media inquiries, please contact:
Kristen Albright
